rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Michael J. Yang

Director

Company insider

Files Form 4 as: Director, Ionis Pharmaceuticals; Director, Pacira BioSciences; EVP and CCO, ACADIA Pharmaceuticals; Director, Akcea Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
72
Buys
1
Sells
7
Bought
$26K
Sold
$7.2M
Companies
4
Companies where not an officer
3
First trade
29 Mar 2017
Last trade
1 Jul 2026
Last filed
6 Jul 2026

Companies traded

Where they are an officer
ACAD ACADIA PharmaceuticalsOfficer · Pharmaceuticals · last 6 Jan 20210 buys · 7 sells
Everywhere else they filed: board seats, 10% stakes, other companies
IONS Ionis PharmaceuticalsDirector · Biotechnology · last 1 Jul 20260 buys · 0 sells
PCRX Pacira BioSciencesDirector · Pharmaceuticals · last 10 Jun 20261 buy · 0 sells
Akcea TherapeuticsDirector · last 12 Oct 20200 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Jul 2026filed 6 Jul 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—5,369 at $0.00filing
1 Jul 2026filed 6 Jul 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—2,301 at $0.00filing
1 Jul 2026filed 6 Jul 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—5,369 at $0.00filing
1 Jul 2026filed 6 Jul 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—2,301 at $0.00filing
10 Jun 2026filed 12 Jun 2026PCRX Pacira BioSciencesPharmaceuticalsSEC FORM 4 Code A—6,405 at $0.00filing
10 Jun 2026filed 12 Jun 2026PCRX Pacira BioSciencesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—10,891 at $0.00filing
10 Jun 2026filed 12 Jun 2026PCRX Pacira BioSciencesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—10,891 at $0.00filing
10 Jun 2026filed 12 Jun 2026PCRX Pacira BioSciencesPharmaceuticalsSEC FORM 4 Code A—6,405 at $0.00filing
15 Jan 2026filed 20 Jan 2026IONS Ionis PharmaceuticalsBiotechnologySEC FORM 4 Code M—1,930 at $0.00filing
15 Jan 2026filed 20 Jan 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—1,930 at $0.00filing
15 Jan 2026filed 20 Jan 2026IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—1,930 at $0.00filing
15 Jan 2026filed 20 Jan 2026IONS Ionis PharmaceuticalsBiotechnologySEC FORM 4 Code M—1,930 at $0.00filing
15 Jul 2025filed 17 Jul 2025IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—4,079 at $0.00filing
15 Jul 2025filed 17 Jul 2025IONS Ionis PharmaceuticalsBiotechnologySEC FORM 4 Code M—4,079 at $0.00filing
1 Jul 2025filed 2 Jul 2025IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—11,518 at $0.00filing
1 Jul 2025filed 2 Jul 2025IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—5,220 at $0.00filing
11 Jun 2025filed 13 Jun 2025PCRX Pacira BioSciencesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—11,279 at $0.00filing
11 Jun 2025filed 13 Jun 2025PCRX Pacira BioSciencesPharmaceuticalsSEC FORM 4 Code A—6,163 at $0.00filing
15 Jan 2025filed 17 Jan 2025IONS Ionis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—1,931 at $0.00filing
15 Jan 2025filed 17 Jan 2025IONS Ionis PharmaceuticalsBiotechnologySEC FORM 4 Code M—1,931 at $0.00filing

News

Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026

0 headlines in the last 90 days name Michael J. Yang; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care8

Buys in green, sells in red, by the company’s sector.

Related people

Mark C. SchneyerEVP, Chief Financial Officer · EVP, Chief Financial Officer at Acadia Pharmaceuticals, filing Form 4 there in the last year
Elizabeth H.Z. ThompsonEVP, Head of Research & Dev · EVP, Head of Research & Dev at Acadia Pharmaceuticals, filing Form 4 there in the last year
James KiharaPrincipal Accounting Officer · Principal Accounting Officer at Acadia Pharmaceuticals, filing Form 4 there in the last year
BAKER BROS. ADVISORS LPDirector and 10% owner · Director and 10% owner at Acadia Pharmaceuticals, filing Form 4 there in the last year
Edmund HarriganDirector · Director at Acadia Pharmaceuticals, filing Form 4 there in the last year
Lauren RikerSenior Vice President, Finance · Also traded PCRX in the last 90 days
Jonathan SloninChief Medical Officer · Also traded PCRX in the last 90 days
Donald J. TrumpPresident · Also traded ACAD in the last 90 days